PIN-1
2
0
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by 9valent Human Papillomavirus Types 6 11 16 18 31 33 45 52 And 58 Recombinant Vaccine Hansenula Polymorpha
Related Conditions
Often studied with 9 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
50%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Research Network
Common Treatments
- 9valent Human Papillomavirus Types 6 11 16 18 31 33 45 52 And 58 Recombinant Vaccine Hansenula Polymorpha1
Active Sponsors
- Shanghai Bovax Biotechnology Co., Ltd.2
Top Investigators
Hunan Provincial Center for Disease Control and Prevention
Obstetrics & Gynecology Hospital of Fudan University
Related Conditions
- Pin32
- Ain22
- Genital Wart2
- Penile Cancer2
- Ain12